<DOC>
	<DOCNO>NCT01964287</DOCNO>
	<brief_summary>Based conventional chemotherapy approach , data indicate Folfirinox regimen effective tolerate treatment Gemcitabine alone patient metastatic pancreatic adenocarcinoma . A recent study combine gemcitabine nab paclitaxel improve objective response rate . Primary objective study identify maximun tolerate dose recommended phase II dose first line treatment combine gemcitabine plus nab-paclitaxel follow folfirinox metastatic pancreatic adenocarcinoma .</brief_summary>
	<brief_title>First Line Treatment Patients With Metastatic Pancreatic Adenocarcinoma .</brief_title>
	<detailed_description>Estimated enrollment : Phase I : 60 Phase II : 53 Study start Date : August 2013 Estimated study completion date : March 2016 Treatment : Gembrax : albumin-bound paclitaxel 30 minute IV follow Gemcitabine 10mg/m²/min IV day 1 , 8 15 follow 2 week rest Folfirinox : Oxaliplatin IV associate LeucovorinIV . After end leucovorin administration , bolus injection 5FU subsequent continuous 5FU 46-hour infusion day 29 43 . Day 1=Day 57</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Histologically cytologically confirm metastatic adenocarcinoma pancreas . The definitive diagnosis metastatic pancreatic adenocarcinoma make integrate histopathological data within context radiologic data . 2 . Initial diagnosis metastatic disease must occur ≤6 week prior inclusion study . 3 . One metastatic tumor measurable metastatic lesion CT scan abdomen , pelvis chest , hepatic MRI CT scan ( abdomen , pelvis chest ) without injection , patient allergic CT contrast medium ) . 4 . No previous radiotherapy , surgery , chemotherapy investigational therapy treatment metastatic disease . 5 . Prior treatment 5 FU gemcitabine administer radiation sensitizer adjuvant setting allow , provide least 6 month relapse since completion last dose linger toxicity present . 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 1 . 7 . Males female age 18 75 year time signing Informed Consent Form ( ICF ) . 8 . Adequate blood function baseline ( obtain within 14 day start study treatment ) 9 . Adequate liver renal function baseline ( obtain within 14 day start study treatment ) 10 . Patient clinical significant abnormality urinalysis result ( obtained ≤ 14 day start study treatment ) 11 . Patient acceptable coagulation value ( obtain ≤14 day prior first administration study drug ) 12 . Patient asymptomatic jaundice prior first administration study drug ( Day1 ) . Significant symptomatic amount ascites drain prior Day 1 . 13 . Pain symptom stable require modification analgesic management prior Day 1 treatment . 14 . Life expectancy ≥ 2 month 15 . Nonpregnant nonlactating female . If female patient childbearing potential , evidence regular menstrual period , must negative serum pregnancy test ( βhCG ) document 72 hour prior randomization . 16 . If sexually active , patient must agree use contraception consider adequate appropriate Investigator period administration study drug . In addition , male female patient must utilize contraception end treatment recommend product 's Summary Product Characteristics Prescribing Information provide study manual . 17 . Informed consent sign prior study specific procedure . 18 . Affiliated French National social security 1 . Known brain metastasis . 2 . Patient locally advance disease . 3 . History malignancy last 5 year . Patients prior history situ cancer basal squamous cell skin cancer eligible . Patients malignancy eligible cured surgery alone surgery plus radiotherapy continuously diseasefree least 5 year . 4 . Patients receive cytotoxic dos chemotherapy ( 5FU gemcitabine ) adjuvant set . 5 . Peripheral sensory neuropathy ≥ grade 2 time sign ICF . 6 . Active uncontrolled bacterial , viral , fungal infection ( ) require systemic therapy . 7 . Known historical active infection HIV . 8 . Major surgery , diagnostic surgery ( i.e . surgery do obtain biopsy diagnosis without removal organ ) , within 4 week prior Day 1 treatment study . 9 . History allergy hypersensitivity study drug excipients , patient exhibit event outline Contraindications Special Warnings Precautions section SmPCs Prescribing Information . 10 . History connective tissue disorder ( e.g. , lupus , scleroderma , arteritis nodosa ) . 11 . Patients high cardiovascular risk , include , limited , coronary stenting myocardial infarction past year . 12 . History Peripheral Artery Disease ( e.g . claudication , Leo Buerger 's disease ) . 13 . Serious medical risk factor involve major organ system , serious psychiatric disorder , could compromise patient 's safety study data integrity . 14 . Enrollment clinical protocol within 4 week sign ICF . 15 . Patient unwilling unable comply study procedure , plan take vacation 7 consecutive day course study . 16 . Legal incapacity limit legal capacity . Medical psychological condition allow subject complete study sign consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>